Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VTAK vs SENS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SENS Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 5–5 Matrix Metrics)

SENS Overall Winner 6-Pillar Tally: VTAK 0 – 5 SENS (1 Tie) Matrix Metrics: VTAK 5 – 5 SENS

As of Nov 16, 2026, Senseonics Holdings, Inc. (SENS) is the stronger overall head-to-head candidate over Catheter Precision, Inc. (VTAK) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VTAK carries a Unified Composite Score of 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin), whereas SENS carries 38.9/100 (SELL) at $10.90 (21.0x Forward P/E, -201.0% operating margin).

  • Composite vs. Pillar Nuance: While VTAK currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. SENS 38.9/100 SELL), SENS captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-201.0% vs. -388.1% operating margin) and revenue trajectory (+141.6% vs. +380.7% YoY).
  • Technical & Structure Timing Caution: VTAK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2); meanwhile SENS trades in a Markup technical trend (CONSOLIDATION options phase, RSI 64.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VTAK vs SENS
VTAK NYSE American
Catheter Precision, Inc.
Surgical & Medical Instruments & Apparatus
$0.15
-0.66% 1D
Market Cap $548,639
TTM Revenue $1.9M
Forward P/E N/M
Beta / 30D Vol 0.19β · 76% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 72.0 Fund 70.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -53.4%), weak momentum, RSI 33
RSI-14: 33.2 · SMA20: $0.16 · SMA50: $0.21
SENS NYSE American Head-to-Head Winner
Senseonics Holdings, Inc.
Industrial Instruments For Measurement, Display, And Control
$10.90
+3.02% 1D
Market Cap $579.6M
TTM Revenue $60M
Forward P/E 21.0x
Beta / 30D Vol 1.98β · 101% Vol
Unified Composite Score
38.9 / 100 SELL
Tech 15.0 Fund 44.0 Flow 57.0 Mom 70.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.6% over 20 days), RSI 65
RSI-14: 64.8 · SMA20: $9.04 · SMA50: $9.20

6-Pillar Scorecard Institutional Category Breakdown (VTAK 0 – 5 SENS)

Columns: Metric · VTAK · SENS
1. Valuation Multiples SENS
Forward P/E N/M 21.0x
Trailing P/E N/M 21.0x
PEG Ratio N/M N/M
EV / Revenue 0.3x 9.9x
2. Growth & Scale SENS
Revenue Growth (YoY) +380.7% +141.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1.9M $60M
Market Cap $548,639 $579.6M
3. Profitability & Quality SENS
Gross Margin 47.7% 58.7%
Operating Margin -388.1% -201.0%
Net Profit Margin 0.0% -204.2%
Return on Equity (ROE) -111.3% -157.3%
4. Balance Sheet & Cash Flow SENS
Cash Generation (TTM) -$10M EBITDA -$114M
Cash Flow Margin N/A N/A
Net Cash / Leverage $4.87 Book/Sh · -111.3% ROE $13M Net Debt (0.79x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SENS
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 68.8% (35th %ile)
Put/Call OI Skew N/A 0.14x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VTAK (5) vs SENS (5)
Institutional Metric VTAK SENS Criterion Row Edge
Market Capitalization
Scale
$548,639 $579.6M Larger Scale SENS
Trailing P/E Ratio
Valuation
N/M 21.0x Lower Multiple SENS
Forward P/E Ratio
Valuation
N/M 21.0x Lower Multiple SENS
Revenue Growth (YoY)
Growth
+380.7% +141.6% Higher Growth VTAK
Operating Margin (TTM)
Profitability
-388.1% -201.0% Higher Margin SENS
Net Profit Margin
Profitability
0.0% -204.2% Higher Margin VTAK
Return on Equity (ROE)
Capital Efficiency
-111.3% -157.3% Higher ROE VTAK
52-Week Range Position
Momentum
1% ($0–$3) 66% ($5–$14) Stronger Trend SENS
Beta / 30D Volatility
Risk Regime
0.19β · 76% Vol 1.98β · 101% Vol Lower Realized Risk VTAK
Unified Institutional Score
Composite Signal
58.1 / 100 (HOLD) 38.9 / 100 (SELL) Higher Composite VTAK
Trailing 12M Revenue (USD)
Operating Scale
$1.9M $60M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
47.7% 58.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.3x EV/Rev N/M PEG · 9.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$10M EBITDA ($4.87 Book/Sh · -111.3% ROE) -$114M ($13M Net Debt (0.79x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SENS +24.16 pp
VTAK: -24.76% · SENS: -0.6%
3M Horizon SENS +155.78 pp
VTAK: -80.29% · SENS: +75.49%
6M Horizon SENS +126.95 pp
VTAK: -83.76% · SENS: +43.19%
1Y Horizon SENS +152.5 pp
VTAK: -92.63% · SENS: +59.87%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VTAK Revenue SENS Revenue VTAK Op. Margin SENS Op. Margin Margin Leader
FY2018 $10M $0M -498.0% -4295.1% VTAK
FY2019 $10M $0M -801.9% -2653.6% VTAK
FY2020 $0M $0M -13668.3% -5784.4% SENS
FY2021 $0M $0M -133027.3% -4102.0% SENS
FY2022 $0M $20M -192578.6% -418.7% SENS
FY2023 $0M $20M -17674.0% -337.7% SENS
FY2024 $0M $20M -2676.9% -333.0% SENS
FY2025 $0M $40M -2581.6% -193.8% SENS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VTAK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VTAK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SENS CONSOLIDATION
37d in phase · OBV ACCUMULATION
Current IV 68.8%
IV Percentile 35th %ile
Put/Call OI Skew 0.14x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact SENS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VTAK Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $548,639 market capitalization and -388.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SENS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $579.6M market capitalization and -201.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VTAK vs SENS Key Questions & Quantitative Answers

As of Nov 16, 2026, Senseonics Holdings, Inc. (SENS) is the stronger overall head-to-head candidate over Catheter Precision, Inc. (VTAK) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VTAK carries a Unified Composite Score of 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin), whereas SENS carries 38.9/100 (SELL) at $10.90 (21.0x Forward P/E, -201.0% operating margin). Composite vs. Pillar Nuance: While VTAK currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. SENS 38.9/100 SELL), SENS captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-201.0% vs. -388.1% operating margin) and revenue trajectory (+141.6% vs. +380.7% YoY). Technical & Structure Timing Caution: VTAK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2); meanwhile SENS trades in a Markup technical trend (CONSOLIDATION options phase, RSI 64.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SENS leads the Growth & Scale pillar: VTAK posts +380.7% YoY revenue growth and +0.0% YoY earnings growth on $1.9M TTM revenue (47.7% gross margin, -388.1% operating margin), compared with SENS at +141.6% YoY revenue growth and +0.0% YoY earnings growth on $60M TTM revenue (58.7% gross margin, -201.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VTAK cumulative revenue shifted +0.0% while SENS shifted +100.0%. In operating R&D and SG&A reinvestment, VTAK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SENS.

SENS screens cheaper on headline valuation multiples. VTAK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (unreported EBITDA margin), whereas SENS trades at 21.0x Forward P/E, 21.0x Trailing P/E, N/M PEG, and 9.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VTAK (-111.3% ROE) versus SENS (-157.3% ROE) capital efficiency.

In options market volatility and institutional positioning, VTAK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.19β · 76% Vol realized risk). By comparison, SENS carries 68.8% implied volatility (35th %ile, Balanced (25th–60th %ile)), a 0.14x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.98β · 101% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.